Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
NurExone Biologic: Technisches (täglich, wöchentlich, monatlich) & Analysten "Strong Buy"-Rating!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QG4Z | ISIN: US67577R1023 | Ticker-Symbol: R3X1
Tradegate
28.03.24
20:35 Uhr
1,876 Euro
+0,018
+0,97 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
OCUPHIRE PHARMA INC Chart 1 Jahr
5-Tage-Chart
OCUPHIRE PHARMA INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,8201,88028.03.
1,8321,88628.03.

Aktuelle News zur OCUPHIRE PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoOcuphire Pharma COO acquires $4.1k in company stock3
MoOcuphire Pharma CFO acquires $21,000 worth of company stock3
20.03.Ocuphire Pharma CEO buys $49,050 in company stock4
08.03.Ocuphire Pharma, Inc. - 10-K, Annual Report5
08.03.Ocuphire Pharma GAAP EPS of -$0.21 misses by $0.21, revenue of $1.69M misses by $4.27M4
08.03.Ocuphire Pharma, Inc. - 8-K, Current Report2
08.03.Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update138FARMINGTON HILLS, Mich., March 08, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule...
► Artikel lesen
04.03.Ocuphire (OCUP) to Report Q4 Earnings: What's in the Cards?7
23.02.Ocuphire Pharma to Present in the BIO CEO & Investor Conference5
16.02.Ocuphire Pharma, Inc. - 8-K, Current Report3
15.02.Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)164FARMINGTON HILLS, Mich., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule...
► Artikel lesen
14.02.Ocuphire Pharma appointed Nirav Jhaveri as CFO3
14.02.Ocuphire Pharma Strengthens Leadership Team with Key Appointments200Ash Jayagopal, Ph.D., M.B.A. Appointed Chief Scientific and Development Officer Nirav Jhaveri, C.F.A, M.B.A. Appointed as Chief Financial Officer FARMINGTON HILLS, Mich., Feb. 14, 2024 (GLOBE NEWSWIRE)...
► Artikel lesen
05.02.Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference5
24.01.Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)6
11.01.Ocuphire Pharma, Inc. - S-8, Securities to be offered to employees in employee benefit plans7
11.01.Here's Why You Should Invest in Ocuphire Pharma (OCUP) Now9
10.01.Ocuphire Pharma files for a $175M mixed securities shelf3
04.01.Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light Conditions199FARMINGTON HILLS, Mich., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule...
► Artikel lesen
06.12.23Ocuphire Pharma, Inc. - 8-K, Current Report4
Seite:  Weiter >>
44 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1